Hints and tips:
Related Special Reports
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
...Paul Hastings O: 6; L: 7; I: 7; Total: 20The firm advised South Korean pharmaceutical company SD Biosensor and South Korean private equity fund SJL Partners on the acquisition of US-listed pharmaceutical...
...over, and poorer countries whose governments are stretched to secure doses for healthcare workers and the most vulnerable....
...Bayer, the German pharmaceutical group, also said it would donate 3m of its malaria tablets, but as they are not approved in the US, they need an emergency authorisation from the FDA....
...The prospect of much lower bond yields — and, crucially, the expectation that central banks will contain any sharp rise — has encouraged investors to boost their exposure to the technology and healthcare...
...Chris Hite, Citigroup’s top healthcare dealmaker, is leaving the US bank to join Royalty Pharma, Bloomberg reported. WeWork has named former Baker Hughes executive Kimberly Ross as its CFO....
...The pharmaceutical and healthcare sectors have been among the most active with $479bn worth of transactions announced....
...healthcare”, in which technology is leveraged, on-demand, to create medication specific to the individual....
...It was this statement of corporate social responsibility — crafted decades before the term became overused PR — which he said had guided the world’s largest healthcare company to become a solid, long-term...
...That puts it ahead of its nearest competitors Johnson & Johnson, Sanofi and Bayer, which hold about 4 per cent market shares each....
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Reckitt cited financial discipline for quitting the two-horse race, as it also did in 2014, when it withdrew from bidding for the healthcare unit of Merck of the US, leaving Germany’s Bayer to clinch the...
...This fourth tranche of 30 ideas (listed below) is about the latest advances in healthcare. The fifth and final chapter, looking at Earth and the universe, will be published on March 29, 2018....
...In 2014, Bayer paid seven times sales to German peer Merck in a $14bn deal....
...Pfizer has said it is looking to sell or spin off its consumer healthcare business in a move that could fetch up to $14bn of cash for the pharmaceuticals group and set off a flurry of dealmaking....
...Pharmaceuticals and PMB’s have pointed fingers at each other for driving up healthcare costs....
...Punit Mehta, global co-head of healthcare at Credit Suisse, agreed that big-ticket deal activity would pick up sooner rather than later....
...Mr Baker, who will join the company from March, is currently chief financial officer at private equity-owned generic pharmaceuticals company Alvogen, and previously spent 20 years at AstraZeneca....
...But Alexander Moscho, UK head of Bayer, the German drugmaker, says the qualy system is not flexible enough for the new world of personalised medicines....
...The former Pfizer and Bayer executive has made dealmaking a key pillar of his strategy to strengthen the pharmaceutical company since taking over last year....
...Halliburton and Baker Hughes also plan to fight the DoJ....
...In pharmaceuticals at least, it is making a comeback....
...Some of the world’s biggest pharmaceuticals groups are facing calls to break up their diversified businesses in favour of greater focus as shareholders push for higher returns on investment....
...Jeffrey Holford, analyst at Jefferies, has touted Bayer as another “logical and motivated” potential acquirer....
...Consumer healthcare was among Bayer’s strongest sources of growth after its $14bn acquisition of over-the-counter medicines from Merck of the US last year....
International Edition